After IPTW, the propensity score-weighted cumulative incidence of cancer was not substantially lower in the factor Xa inhibitor cohort (2,157/23,711; 9.11%, 95% CI [8.61%,9.63%]) than in the dabigatran cohort (2,294/23,715; 9.68%, 95% CI [9.14%,10.25%]; SHR 0.94, 95% CI 0.89 to 1.00; Fig 1). The gene discussed is F10; the disease is cancer.